181 related articles for article (PubMed ID: 16630341)
1. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
Campbell KJ; O'Shea JM; Perkins ND
BMC Cancer; 2006 Apr; 6():101. PubMed ID: 16630341
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response.
Karl S; Pritschow Y; Volcic M; Häcker S; Baumann B; Wiesmüller L; Debatin KM; Fulda S
J Cell Mol Med; 2009 Oct; 13(10):4239-56. PubMed ID: 19725919
[TBL] [Abstract][Full Text] [Related]
3. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Bottero V; Busuttil V; Loubat A; Magné N; Fischel JL; Milano G; Peyron JF
Cancer Res; 2001 Nov; 61(21):7785-91. PubMed ID: 11691793
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
5. Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin.
Bednarski BK; Baldwin AS; Kim HJ
PLoS One; 2009 Sep; 4(9):e6992. PubMed ID: 19746155
[TBL] [Abstract][Full Text] [Related]
6. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
7. Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer.
Wu W; Ma B; Ye H; Wang T; Wang X; Yang J; Wei Y; Zhu J; Chen L
Oncotarget; 2016 Aug; 7(32):52281-52293. PubMed ID: 27447570
[TBL] [Abstract][Full Text] [Related]
8. DNA damage independent inhibition of NF-κB transcription by anthracyclines.
Chora AF; Pedroso D; Kyriakou E; Pejanovic N; Colaço H; Gozzelino R; Barros A; Willmann K; Velho T; Moita CF; Santos I; Pereira P; Carvalho S; Martins FB; Ferreira JA; de Almeida SF; Benes V; Anrather J; Weis S; Soares MP; Geerlof A; Neefjes J; Sattler M; Messias AC; Neves-Costa A; Moita LF
Elife; 2022 Dec; 11():. PubMed ID: 36476511
[TBL] [Abstract][Full Text] [Related]
9. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity.
Andrivon W; Saucier JM; Auclair C; Monneret C; Florent JC; Guillosson JJ; Nafziger J
Leuk Res; 1996 Feb; 20(2):119-26. PubMed ID: 8628010
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.
Pérez C; Vilaboa NE; García-Bermejo L; de Blas E; Creighton AM; Aller P
J Cell Sci; 1997 Feb; 110 ( Pt 3)():337-43. PubMed ID: 9057086
[TBL] [Abstract][Full Text] [Related]
11. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C.
Das KC; White CW
J Biol Chem; 1997 Jun; 272(23):14914-20. PubMed ID: 9169462
[TBL] [Abstract][Full Text] [Related]
12. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues.
Ashikawa K; Shishodia S; Fokt I; Priebe W; Aggarwal BB
Biochem Pharmacol; 2004 Jan; 67(2):353-64. PubMed ID: 14698047
[TBL] [Abstract][Full Text] [Related]
13. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of anticancer drugs targeted to topoisomerase II.
Hande KR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):173-84. PubMed ID: 9748560
[TBL] [Abstract][Full Text] [Related]
15. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
16. Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells.
Kato M; Nakayama M; Agata M; Yoshida K
Tumour Biol; 2013 Apr; 34(2):723-33. PubMed ID: 23247865
[TBL] [Abstract][Full Text] [Related]
17. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity.
Biswas SK; McClure D; Jimenez LA; Megson IL; Rahman I
Antioxid Redox Signal; 2005; 7(1-2):32-41. PubMed ID: 15650394
[TBL] [Abstract][Full Text] [Related]
18. Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Tabata M; Tabata R; Grabowski DR; Bukowski RM; Ganapathi MK; Ganapathi R
J Biol Chem; 2001 Mar; 276(11):8029-36. PubMed ID: 11115510
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents.
Perrin D; van Hille B; Hill BT
Biochem Pharmacol; 1998 Aug; 56(4):503-7. PubMed ID: 9763227
[TBL] [Abstract][Full Text] [Related]
20. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.
Campbell KJ; Rocha S; Perkins ND
Mol Cell; 2004 Mar; 13(6):853-65. PubMed ID: 15053878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
